

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** ( Not for submission under 37 CFR 1.99)

Application Number	10564009
Filing Date	2006-01-09
First Named Inventor	BEROOZ SHARIFI
Art Unit	1636
Examiner Name	n/a
Attorney Docket Number	67789-516

## **U.S.PATENTS**

[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6572851		2003-06-03	MURAMATSU	
	2	6383480		2002-05-07	KIKUCHI	
	3	6364912		2002-04-02	PETERSON	
	4	6136600		2000-10-24	SATO	

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

## **U.S.PATENT APPLICATION PUBLICATIONS**

[Remove](#)

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030118585		2003-06-26	MUELLER	
	2	20020132984		2002-09-19	KIKUCHI ET AL.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10564009	10564009 - GAU: 1633
Filing Date	2006-01-09	
First Named Inventor	BEROOZ SHARIFI	
Art Unit	1636	
Examiner Name	n/a	
Attorney Docket Number	67789-516	

3	20020182242		2002-12-05	PETERSON ET AL.	
4	20020034768		2002-03-21	WELLSTEIN	
5	20020114780		2002-08-22	BANKIEWICZ ET AL.	
6	20030118585		2003-06-26	MULLER ET AL.	

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

**FOREIGN PATENT DOCUMENTS**

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	WO9602257	WO		1996-02-01	GEORGETOWN UNIV		<input checked="" type="checkbox"/>
	2	WO9824457	WO		1998-06-11	GEORGETOWN UNIV		<input checked="" type="checkbox"/>
	3	WO0020869	WO		2000-04-13	GEORGETOWN UNIV		<input checked="" type="checkbox"/>
	4	WO0208415	WO		2003-05-02	JAPAN SCIENCE TECH CORP		<input type="checkbox"/>
	5	WO9953943	WO		1999-10-28	ANGIOGENIX INC.		<input checked="" type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10564009	10564009 - GAU: 1633
Filing Date	2006-01-09	
First Named Inventor	BEROOZ SHARIFI	
Art Unit	1636	
Examiner Name	n/a	
Attorney Docket Number	67789-516	

6	WO0164944	WO		2001-09-07	BARNES JEWISH HOSP	<input checked="" type="checkbox"/>
7	WO0196394	WO		2001-12-20	WELLSTEIN ANTON; UNIV GEORGETOWN MED CENTER	<input checked="" type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	SOUTTOU B. et al. "Pleiotrophin induces angiogenesis: involvement of the phosphoinositide-3 kinase but not the nitric oxide synthase pathways," Journal of Cellular Physiology, 2001, Vol. 187, pps. 59-64.	<input type="checkbox"/>
	2	HERRADON G. et al. "Pleiotrophin is an important regulator of the renin-angiotensin system in mouse aorta," Biochem Biophys Res Commun. 2004, Vol. 324, No. 3, pps 1041-1047.	<input type="checkbox"/>
	3	DEUEL T.F. et al. "Pleiotrophin: a cytokine with diverse functions and a novel signaling pathway," Arch Biochem Biophys. 2002, Vol. 397, No. 2, pps. 162-171.	<input type="checkbox"/>
	4	CZUBAYKO F. et al. "Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation," Gene Therapy, 1997, Vol. 4, pps. 943-949.	<input type="checkbox"/>
	5	FANG W. et al. "Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer," J. Biol Chem. December 1992, Vol. 267, No. 36, pps. 25889-25897.	<input type="checkbox"/>
	6	YEH H.J. et al. "Upregulation of pleiotrophin gene expression in developing microvasculature, macrophages, and astrocytes after acute ischemic brain injury," J. Neurosci. 18, 3699-707 (1998).	<input type="checkbox"/>
	7	ACHOUR A. et al. "The angiogenic factor heparin affin regulatory peptide (HARP) induces proliferation of human peripheral blood mononuclear cells," Cell Mol. Biol. (Noisy-le-grand) 47 Online Pub, OL73-7 (2001).	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10564009	10564009 - GAU: 1633
Filing Date	2006-01-09	
First Named Inventor	BEROOZ SHARIFI	
Art Unit	1636	
Examiner Name	n/a	
Attorney Docket Number	67789-516	

8	MURAMATSU T. "Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis," J. Biochem (Tokyo) 132, 359-71 (2002).	<input type="checkbox"/>
9	TAKEDA A. et al. "Induction of heparin-binding growth-associated molecule expression in reactive astrocytes following hippocampal neuronal injury," Neuroscience 68, 57-64 (1995).	<input type="checkbox"/>
10	PUFE T. et al. "Expression of pleiotrophin, an embryonic growth and differentiation factor, in rheumatoid arthritis," Arthritis Rheum 48, 660-7 (2003).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Kevin Hill/	Date Considered	07/28/2009
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.